Cellular Therapy
Conference Coverage
Xenon imaging could detect lung involvement after HSCT
SALT LAKE CITY – Non-ionizing imaging technique could reveal early lung ventilation deficits in children undergoing hematopoietic stem cell...
Conference Coverage
CAR T before transplant yields durable remission in B-cell malignancies
SALT LAKE CITY – The analysis also showed the value of next-generation sequencing in detecting relapse earlier than flow cytometry can.
Conference Coverage
KD025 shows promise for steroid-dependent cGVHD
SALT LAKE CITY – The ROCK2-selective inhibitor KD025 is demonstrating encouraging activity and safety in steroid-dependent cGVHD in a phase 2a...
Conference Coverage
Nonmyeloablative conditioning gets a radiation boost for severe hemoglobinopathies
SALT LAKE CITY – Doubling total body irradiation reduced graft rejection without increasing toxicity for patients with sickle cell disease or beta...
Conference Coverage
Outpatient CAR T infusions feasible using liso-cel
SALT LAKE CITY – Though most patients are admitted later, hospital stays are shorter with outpatient CAR T infusion.
Latest News
Cancer groups offer guidance on immune-related adverse events
Both ASCO and NCCN have released guidelines with tips for managing the side effects of cancer immunotherapy agents.
Conference Coverage
High efficacy, no safety signals for herpes zoster vaccine post-HSCT
SALT LAKE CITY – The vaccine could offer safe, effective protection against herpes zoster in myeloma patients who are immunosuppressed.
Latest News
HCT-CI score may predict mortality for nonmalignant disease
SALT LAKE CITY – The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) is useful in hematologic malignancies, but it may also be...
From the Journals
Tisagenlecleucel looks effective in phase 2 study of young ALL patients
Tisagenlecleucel had transitory but high-grade toxicity in this population of children and young adults.
From the Journals
Checkpoint inhibitors look safe in rheumatology patients
The Mayo Clinic analysis examines 16 patients with rheumatologic diseases and cancer who received checkpoint inhibitor therapy.
From the Journals
A mismatched haplotype may improve outcomes in second BMT
Mortality risk was highest in patients who had progressive or refractory disease before a second transplant, or who relapsed within 6 months of a...